<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
      <journal-id journal-id-type="publisher-id">plos</journal-id>
      <journal-id journal-id-type="pmc">plosone</journal-id>
      <journal-title-group>
        <journal-title>PLoS ONE</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1932-6203</issn>
      <publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">PONE-D-12-23724</article-id>
      <article-id pub-id-type="doi">10.1371/journal.pone.0052145</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline-v2">
          <subject>Medicine</subject>
          <subj-group>
            <subject>Cardiovascular</subject>
            <subj-group>
              <subject>Cardiovascular pharmacology</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Clinical research design</subject>
            <subj-group>
              <subject>Clinical trials</subject>
              <subject>Meta-analyses</subject>
              <subject>Systematic reviews</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Epidemiology</subject>
            <subj-group>
              <subject>Clinical epidemiology</subject>
              <subject>Pharmacoepidemiology</subject>
            </subj-group>
          </subj-group>
          <subj-group>
            <subject>Public health</subject>
            <subj-group>
              <subject>Preventive medicine</subject>
            </subj-group>
          </subj-group>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Public Health and Epidemiology</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials</article-title>
        <alt-title alt-title-type="running-head">Meta-Analysis of Polypills</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Elley</surname>
            <given-names>C Raina</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Ajay K.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Webster</surname>
            <given-names>Ruth</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Selak</surname>
            <given-names>Vanessa</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Jun</surname>
            <given-names>Min</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Anushka</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Rodgers</surname>
            <given-names>Anthony</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Thom</surname>
            <given-names>Simon</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
            <sup>2</sup>
          </xref>
        </contrib>
      </contrib-group>
      <aff id="aff1">
        <label>1</label>
        <addr-line>School of Population Health, University of Auckland, Auckland, New Zealand</addr-line>
      </aff>
      <aff id="aff2">
        <label>2</label>
        <addr-line>International Centre for Circulatory Health, Imperial College, London, United Kingdom</addr-line>
      </aff>
      <aff id="aff3">
        <label>3</label>
        <addr-line>The George Institute for Global Health, University of Sydney, Sydney, Australia</addr-line>
      </aff>
      <contrib-group>
        <contrib contrib-type="editor" xlink:type="simple">
          <name name-style="western">
            <surname>Wright</surname>
            <given-names>James M.</given-names>
          </name>
          <role>Editor</role>
          <xref ref-type="aff" rid="edit1"/>
        </contrib>
      </contrib-group>
      <aff id="edit1">
        <addr-line>University of British Columbia, Canada</addr-line>
      </aff>
      <author-notes>
        <corresp id="cor1">* E-mail: <email xlink:type="simple">c.elley@auckland.ac.nz</email></corresp>
        <fn fn-type="conflict">
          <p>The authors have read the journal's policy and have the following conflicts: AR and RW have received a grant from Dr Reddy's Ltd (DRL) for the SPACE collaboration centre but this is unrelated to the current meta-analysis. DRL also provided a fixed dose combination formulation free of charge for four randomized controlled trials to assess the effectiveness of a “polypill-based strategy.” CRE, VS, AP, ST and AR are investigators or are on the steering committee of at least one of these trials. The George Institute for Global Health is now negotiating a global license for these products, following a decision by DRL not to proceed with taking the products to market because of existing regulatory requirements. DRL has provided travel assistance to meetings on “polypills” for CRE, RW, VS, AP, ST and AR in the past. AKG has received travel assistance to attend a conference from Pfizer. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.</p>
        </fn>
        <fn fn-type="con">
          <p>Conceived and designed the experiments: CRE AKG RW VS MJ AP AR ST. Performed the experiments: CRE AKG VS. Analyzed the data: CRE AKG VS. Contributed reagents/materials/analysis tools: CRE AKG VS. Wrote the paper: CRE AKG RW VS MJ AP AR ST. Contributed to literature search strategy: RW MJ. Critically appraised analyses:W MJ AP AR ST. Contributed to interpretation of results: RW MJ AP AR ST.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="collection">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>19</day>
        <month>12</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <issue>12</issue>
      <elocation-id>e52145</elocation-id>
      <history>
        <date date-type="received">
          <day>8</day>
          <month>8</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>8</day>
          <month>11</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Elley et al</copyright-holder>
        <license xlink:type="simple">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Background</title>
          <p>To assess the blood pressure and lipid-lowering efficacy and tolerability of ‘polypills’ used in cardiovascular disease prevention trials.</p>
        </sec>
        <sec>
          <title>Methodology/Principal Findings</title>
          <p>Systematic review and meta-analysis. <italic>Search strategy:</italic> The Cochrane Central Register of Controlled Trials, Medline, and PubMed databases were searched for eligible trials. <italic>Study inclusion criteria</italic>: Randomised controlled trials of at least six weeks duration, which compared a ‘polypill’ (that included at least one anti-hypertensive and one lipid-lowering medication) with a placebo (or one active component). <italic>Outcome measures:</italic> Change from baseline in systolic and diastolic blood pressures, and total and LDL-cholesterol; discontinuation of study medication and reported adverse effects. Of 44 potentially eligible studies, six trials (including 2,218 patients without previous cardiovascular disease) fulfilled the inclusion criteria. Compared with placebo, ‘polypills’ reduced systolic blood pressure by −9.2 mmHg (95% confidence interval (CI): −13.4, −5.0) diastolic blood pressure by −5.0 mmHg (95%CI: −7.4, −2.6), total cholesterol by −1.22 mmol/L (95%CI: −1.60, −0.84) and LDL-cholesterol by −1.02 mmol/L (95%CI: −1.37, −0.67). However, those taking a ‘polypill’ (vs. placebo or component) were more likely to discontinue medication (20% vs 14%) (Odds ratio: 1.5 (95% CI: 1.2, 1.9)). There was no significant difference in reported adverse effects amongst those on a ‘polypill’ (36% vs. 28%) (OR: 1.3 (95%CI: 0.7, 2.5)). There was high statistical heterogeneity in comparisons for blood pressure and lipid-lowering but use of random-effects and quality-effects models produced very similar results.</p>
        </sec>
        <sec>
          <title>Conclusions/Significance</title>
          <p>Compared with placebo, the ‘polypills’ reduced blood pressure and lipids. Tolerability was lower amongst those on ‘polypills’ than those on placebo or one component, but differences were moderate. Effectiveness trials are needed to help clarify the status of ‘polypills’ in primary care and prevention strategies.</p>
        </sec>
      </abstract>
      <funding-group>
        <funding-statement>The authors did not receive any extrenal funding for this project. Therefore funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
      </funding-group>
      <counts>
        <page-count count="10"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec id="s1">
      <title>Introduction</title>
      <p>Cardiovascular disease is the leading cause of death worldwide. <xref ref-type="bibr" rid="pone.0052145-World1">[1]</xref> On the basis of a substantial body of evidence, cardiovascular guidelines have recommended that those with a past history of cardiovascular disease <xref ref-type="bibr" rid="pone.0052145-National1">[2]</xref> or who otherwise have a high risk of disease <xref ref-type="bibr" rid="pone.0052145-New1">[3]</xref> follow lifestyle interventions and receive blood pressure lowering <xref ref-type="bibr" rid="pone.0052145-Law1">[4]</xref> and lipid-lowering medications, <xref ref-type="bibr" rid="pone.0052145-Law2">[5]</xref>, <xref ref-type="bibr" rid="pone.0052145-Cholesterol1">[6]</xref> and where benefit outweighs risk, aspirin therapy. <xref ref-type="bibr" rid="pone.0052145-AntithromboticTrialists1">[7]</xref>, <xref ref-type="bibr" rid="pone.0052145-US1">[8]</xref> This combination of therapies substantially reduces risk of future cardiovascular events. <xref ref-type="bibr" rid="pone.0052145-Yusuf1">[9]</xref>, <xref ref-type="bibr" rid="pone.0052145-Murray1">[10]</xref>, <xref ref-type="bibr" rid="pone.0052145-Wald1">[11]</xref> Despite guidelines, high proportions of those at high cardiovascular risk are not prescribed these preventive medications, particularly in low income countries. <xref ref-type="bibr" rid="pone.0052145-Elley1">[12]</xref>, <xref ref-type="bibr" rid="pone.0052145-Yusuf2">[13]</xref>, <xref ref-type="bibr" rid="pone.0052145-Selak1">[14]</xref> Besides relatively low rates of prescribing of recommended medications, long-term adherence to medications is also low, which further compromises the preventive potential of these medications. A 2003 World Health Organisation (WHO) report estimated that less than 50% of those prescribed long-term medications for chronic conditions take their medications regularly. <xref ref-type="bibr" rid="pone.0052145-World2">[15]</xref> Each additional cardiovascular medication prescribed tends to be associated with lower adherence. <xref ref-type="bibr" rid="pone.0052145-Kulkarni1">[16]</xref> Adherence also reduces sharply in the first year after commencing medication, although adherence is better if medications are initiated together. <xref ref-type="bibr" rid="pone.0052145-World2">[15]</xref>, <xref ref-type="bibr" rid="pone.0052145-Chapman1">[17]</xref> The WHO report recommends that interventions to improve adherence should be developed and could improve health outcomes to a greater extent than developing new medications. <xref ref-type="bibr" rid="pone.0052145-World2">[15]</xref> Using fixed dose combinations, or ‘polypills’, that combine generic versions of different classes of preventive medications for high risk individuals is one such strategy, as it may simplify the medication regime for both prescriber and patient and reduce cost for health funder and patient. <xref ref-type="bibr" rid="pone.0052145-Gaziano1">[18]</xref>, <xref ref-type="bibr" rid="pone.0052145-Lafeber1">[19]</xref>.</p>
      <p>In 2001, a WHO and Wellcome Trust meeting of experts concluded that a fixed-dose combination pill containing aspirin, statin and two blood pressure (BP) lowering agents may improve adherence to treatment as well as substantially reduce the cost of the drugs, particularly for low and middle income countries. <xref ref-type="bibr" rid="pone.0052145-World3">[20]</xref> In 2003, Wald and Law claimed that ischemic heart disease could be reduced by 88% and strokes by 80% if all those over 55 years of age were given a ‘polypill’ containing three low-dose blood pressure lowering medications, a statin, low dose aspirin and folic acid. <xref ref-type="bibr" rid="pone.0052145-Wald1">[11]</xref> This controversial approach of ‘medicalising’ the population has been followed by more targeted approaches of ‘polypills’ recommended for high risk individuals only, where effectiveness and cost-effectiveness are likely to be most favourable. <xref ref-type="bibr" rid="pone.0052145-Lonn1">[21]</xref> An important aspect of the ‘polypills’ is their affordability, particularly for low-income countries where cardiovascular mortality is increasing. <xref ref-type="bibr" rid="pone.0052145-Strong1">[22]</xref>.</p>
      <p>Evidence for fixed-dose combination (FDC) medications has been promising, as shown by a meta-analysis of antihypertensive FDCs. <xref ref-type="bibr" rid="pone.0052145-Gupta1">[23]</xref> In 2002, the WHO recommended that bioavailability, pharmacokinetics, effects on risk factors and side effects of ‘polypill’ formulations should be assessed by short-term efficacy trials, followed by community-based effectiveness trials and cost-effectiveness evaluations comparing ‘polypills’ to standard practice. <xref ref-type="bibr" rid="pone.0052145-World3">[20]</xref> It has taken more than 10 years to progress these aims. Several efficacy trials of ‘polypills’ including at least one antihypertensive and one lipid-lowering medication have been conducted. Some are placebo-controlled while others have active component comparators. This systematic review and meta-analysis aimed to assess the efficacy and tolerability of the ‘polypill’ approach by examining the effects on blood pressure, lipid profiles and discontinuation and side effects of medication.</p>
    </sec>
    <sec id="s2" sec-type="methods">
      <title>Methods</title>
      <sec id="s2a">
        <title>Ethics Statement</title>
        <p>This was a meta-analysis of published summary data and therefore did not require ethics approval.</p>
      </sec>
      <sec id="s2b">
        <title>Definition of a ‘Polypill’</title>
        <p>For the purposes of this review, a ‘polypill’ has been defined as a medication formulation containing at least one blood pressure lowering medication and one lipid-lowering medication (with or without an anti-platelet agent such as aspirin).</p>
      </sec>
      <sec id="s2c">
        <title>Selection of Studies</title>
        <p>This meta-analysis included randomised controlled trials of cardiovascular ‘polypills’ that were published in English. Trials of at least six weeks duration were eligible to allow reasonable estimation of clinical effect and likely discontinuation of medication. Trials must have assessed at least one primary outcome of this review, which included systolic and diastolic blood pressure, serum total and LDL-cholesterol and a measure of tolerability, either discontinuation of medication or proportion reporting side effects. The comparator could be placebo or component medications that allowed a placebo comparison for at least one primary outcome.</p>
        <p>The Cochrane Central Register of Controlled Trials, Medline, and PubMed databases were searched for eligible trials using the terms in <xref ref-type="supplementary-material" rid="pone.0052145.s004">Table S1</xref>. The strategy was guided by the Cochrane Systematic Review Handbook. <xref ref-type="bibr" rid="pone.0052145-Cochrane1">[24]</xref> Reference lists were also searched. A second researcher undertook an independent literature search of Medline, PubMed and Embase (<xref ref-type="supplementary-material" rid="pone.0052145.s005">Table S2</xref>).</p>
      </sec>
      <sec id="s2d">
        <title>Study Procedures</title>
        <p>Data were extracted on design, intervention, duration of follow-up, sample size (intervention and control) and follow-up rate. Study population demographic, cardiovascular risk and co-morbidity characteristics were also recorded. Data extraction was undertaken separately by two researchers. Study quality was assessed using the Jadad criteria where a score out of five is given for description and appropriateness of randomisation and blinding, and for description of withdrawals and drop-outs. <xref ref-type="bibr" rid="pone.0052145-Jadad1">[25]</xref> The Cochrane criteria for risk of bias were also used to assess study quality. <xref ref-type="bibr" rid="pone.0052145-Cochrane1">[24]</xref> Change in outcome measures in each group over the trial was recorded. Authors were contacted where data were missing. The number and proportion of study participants who discontinued the study medication during the trial and the proportion of participants with side effects were compared between intervention and control groups.</p>
      </sec>
      <sec id="s2e">
        <title>Statistical Analysis</title>
        <p>The weighted mean difference in continuous outcomes was calculated using Cochrane RevMan 5.1 software <xref ref-type="bibr" rid="pone.0052145-Cochrane1">[24]</xref> and checked by a separate researcher using STATA (v12, StataCorp LP). Means and standard deviations of change of the primary outcome measures were used where reported. Where standard deviations could not be obtained from the published data or from contacting the authors, standard deviations from baseline were used. <xref ref-type="bibr" rid="pone.0052145-Furukawa1">[26]</xref> Where there was no placebo control, comparators not containing an anti-hypertensive for blood pressure analyses or not containing a lipid-lowering medication for lipid analyses were used. Odds ratios and 95% confidence intervals were calculated for dichotomous variables. Heterogeneity was investigated using Tau<sup>2</sup> and I<sup>2</sup> statistics. Where substantial statistical heterogeneity was found, random-effects models were used and compared with quality-effects models. <xref ref-type="bibr" rid="pone.0052145-Doi1">[27]</xref> Publication bias was investigated using Begg’s rank correlation and Egger’s regression methods in STATA v12, and funnel plots in RevMan. <xref ref-type="bibr" rid="pone.0052145-Begg1">[28]</xref>, <xref ref-type="bibr" rid="pone.0052145-Egger1">[29]</xref>, <xref ref-type="bibr" rid="pone.0052145-Sterne1">[30]</xref> Sensitivity analyses were carried out on the basis of duration of follow-up, as it was hypothesized that effect size may reduce if adherence decreased over time.</p>
      </sec>
    </sec>
    <sec id="s3">
      <title>Results</title>
      <p>Of the 44 studies identified by the literature search, six fulfilled the inclusion criteria and were included in the meta-analysis (<xref ref-type="fig" rid="pone-0052145-g001">Figure 1</xref> and <xref ref-type="supplementary-material" rid="pone.0052145.s004">Table S1</xref>). A search undertaken independently by a second researcher did not identify any additional eligible studies (<xref ref-type="supplementary-material" rid="pone.0052145.s001">Figure S1</xref>). The characteristics and quality of the eligible studies are included in <xref ref-type="table" rid="pone-0052145-t001">Table 1</xref>.</p>
      <fig id="pone-0052145-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0052145.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>Polypills Meta-analysis ‘PRISMA’ Flow Diagram.</title>
        </caption>
        <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052145.g001" position="float" xlink:type="simple"/>
      </fig>
      <table-wrap id="pone-0052145-t001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pone.0052145.t001</object-id>
        <label>Table 1</label>
        <caption>
          <title>Baseline Characteristics and Study Quality of included Randomised Controlled Trials.</title>
        </caption>
        <alternatives>
          <graphic id="pone-0052145-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052145.t001" xlink:type="simple"/>
          <table>
            <colgroup span="1">
              <col align="left" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
              <col align="center" span="1"/>
            </colgroup>
            <thead>
              <tr>
                <td align="left" rowspan="1" colspan="1">IncludedStudy</td>
                <td align="left" rowspan="1" colspan="1">Study population characteristics</td>
                <td align="left" rowspan="1" colspan="1">Mean age (SD); female gender (%)</td>
                <td align="left" rowspan="1" colspan="1">Mean SBP(SD)/DBP (SD) mmHg</td>
                <td align="left" rowspan="1" colspan="1">Mean total cholesterol (SD); LDL (SD) mmol/L</td>
                <td align="left" rowspan="1" colspan="1">‘Polypill’ contents (dose); n</td>
                <td align="left" rowspan="1" colspan="1">Comparison; n</td>
                <td align="left" rowspan="1" colspan="1">Duration of follow-up;</td>
                <td align="left" rowspan="1" colspan="1">Outcomes assessed;</td>
                <td align="left" rowspan="1" colspan="1">Study quality (Jadad score <xref ref-type="bibr" rid="pone.0052145-Jadad1">[25]</xref>)</td>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Grimm et al.2010 <xref ref-type="bibr" rid="pone.0052145-Grimm1">[31]</xref><xref ref-type="table-fn" rid="nt101">*</xref></td>
                <td align="left" rowspan="1" colspan="1">Primary prevention (no previousCVD) Inclusion criteria: Any CVDrisk factor but no diabetes</td>
                <td align="left" rowspan="1" colspan="1">56 (range 24–84); 50%</td>
                <td align="left" rowspan="1" colspan="1">132.6 (11.8)/81.5 (8.9)</td>
                <td align="left" rowspan="1" colspan="1">5.48 (0.78); 3.35 (0.60)</td>
                <td align="left" rowspan="1" colspan="1">Amlodipine (5–10 mg) Atorvastatin (20 mg); n = 122</td>
                <td align="left" rowspan="1" colspan="1">Amlodipine (5–10 mg); n = 122</td>
                <td align="left" rowspan="1" colspan="1">6 weeks</td>
                <td align="left" rowspan="1" colspan="1">SBP, DBP<xref ref-type="table-fn" rid="nt101">*</xref>, Total cholesterol, LDL, AEs;</td>
                <td align="left" rowspan="1" colspan="1">Jadad 5/5; 89% follow-up</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Malekzadeh et al.2010 <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref><xref ref-type="table-fn" rid="nt101">*</xref></td>
                <td align="left" rowspan="1" colspan="1">Primary prevention (no previousCVD) Inclusion criteria: &gt;50/55 yrs,no previous CVD; not on active BPor lipid lowering medications. No exclusionfor diabetes</td>
                <td align="left" rowspan="1" colspan="1">59.1 (6.9); 33%</td>
                <td align="left" rowspan="1" colspan="1">127.5 (17.3)/79.8 (10.1)</td>
                <td align="left" rowspan="1" colspan="1">5.26 (1.01); 2.99 (0.68)</td>
                <td align="left" rowspan="1" colspan="1">Aspirin (81 mg), Enalapril (2.5 mg), Atorvastatin (20 mg) and Hydrochloro-thiazide (12.5 mg); n = 241</td>
                <td align="left" rowspan="1" colspan="1">Placebo; n = 234</td>
                <td align="left" rowspan="1" colspan="1">12 months</td>
                <td align="left" rowspan="1" colspan="1">SBP, DBP, Total cholesterol, LDL, AEs;</td>
                <td align="left" rowspan="1" colspan="1">Jadad 4/5; Imbalance in baseline chchs suggests inadequacy of randomisation; Low follow-up rate: 68% in intervention, 78% in control</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Neutel et al.2009 <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref><xref ref-type="table-fn" rid="nt101">*</xref></td>
                <td align="left" rowspan="1" colspan="1">Primary prevention (no previousCVD) Inclusion criteria: Hypertensionor dyslipidaemia but no diabetesand not on any treatment</td>
                <td align="left" rowspan="1" colspan="1">52.9 (10.7);54%</td>
                <td align="left" rowspan="1" colspan="1">146.5 (10.0)/91.1 (6.8)</td>
                <td align="left" rowspan="1" colspan="1">5.65 (0.72); 3.46 (0.60)</td>
                <td align="left" rowspan="1" colspan="1">Amlodipine (5 mg) Atorvastatin (20 mg)(plus TLC);n = 66</td>
                <td align="left" rowspan="1" colspan="1">Placebo (plus TLC); n = 64</td>
                <td align="left" rowspan="1" colspan="1">8 weeks</td>
                <td align="left" rowspan="1" colspan="1">SBP, DBP. Total cholesterol, LDL, AEs;</td>
                <td align="left" rowspan="1" colspan="1">Jadad 4/5; 90% follow-up</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Pill Collaborative2011 <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref></td>
                <td align="left" rowspan="1" colspan="1">Primary prevention (no previousCVD) Inclusion criteria: 5-yr CVD risk&gt;7.5% (based on Framinghamrisk score) or 5%–7.5% and 2 CVDrisk factors. No exclusionfor diabetes</td>
                <td align="left" rowspan="1" colspan="1">61.4 (7.2); 19%</td>
                <td align="left" rowspan="1" colspan="1">134.0 (13.5)/80.5 (9.0)</td>
                <td align="left" rowspan="1" colspan="1">5.50 (1.05); 3.65 (0.90)</td>
                <td align="left" rowspan="1" colspan="1">Aspirin (75 mg), Lisinopril (10 mg) Hydrochlorothiazide (12.5 mg) and Simvastatin (20 mg); n = 189</td>
                <td align="left" rowspan="1" colspan="1">Placebo; n = 189</td>
                <td align="left" rowspan="1" colspan="1">12 weeks</td>
                <td align="left" rowspan="1" colspan="1">SBP, DBP, Total cholesterol, LDL, AEs;</td>
                <td align="left" rowspan="1" colspan="1">Jadad 5/5; 99% follow-up and some imbalance in baseline SBP</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Wald2012 <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref></td>
                <td align="left" rowspan="1" colspan="1">Primary prevention (no previousCVD) Inclusion criteria: over50 years of age</td>
                <td align="left" rowspan="1" colspan="1">59 (range 51–77); 26%</td>
                <td align="left" rowspan="1" colspan="1">143.0 (16)/86.0 (10)<xref ref-type="table-fn" rid="nt102">**</xref></td>
                <td align="left" rowspan="1" colspan="1">5.9 (1.0); 3.7 (0.9)<xref ref-type="table-fn" rid="nt102">**</xref></td>
                <td align="left" rowspan="1" colspan="1">Amlodipine (2.5 mg) Losartan (25 mg), Hydrochlorothiazide (12.5 mg) and Simvastatin (40 mg); n = 86</td>
                <td align="left" rowspan="1" colspan="1">Placebo; n = 86</td>
                <td align="left" rowspan="1" colspan="1">12 weeks (cross-over RCT)</td>
                <td align="left" rowspan="1" colspan="1">SBP, DBP, Total cholesterol, LDL, AEs</td>
                <td align="left" rowspan="1" colspan="1">Jadad 5/5; 98% follow-up</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">The IndianPolycap Study ‘TIPS’2009 <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref><xref ref-type="table-fn" rid="nt103">#</xref></td>
                <td align="left" rowspan="1" colspan="1">Primary prevention (no previous CVD) Inclusion criteria: at least one CV risk factor (including diabetes)</td>
                <td align="left" rowspan="1" colspan="1">53.6 (7.7); 44%</td>
                <td align="left" rowspan="1" colspan="1">134.3 (12.3)/85.2 (8.1)</td>
                <td align="left" rowspan="1" colspan="1">4.7 (0.9); 3.0 (0.8)</td>
                <td align="left" rowspan="1" colspan="1">Hydrochlorothiazide (12·5 mg), Atenolol (50 mg), Ramipril (5 mg), Simvastatin (20 mg), Aspirin (100 mg); n = 412</td>
                <td align="left" rowspan="1" colspan="1">Aspirin (100 mg); n = 205 (Simvastatin 20 mg group added for BP comparison n = 202)</td>
                <td align="left" rowspan="1" colspan="1">12 weeks (some 8–12 weeks);</td>
                <td align="left" rowspan="1" colspan="1">SBP, DBP, Total cholesterol, LDL, AEs;</td>
                <td align="left" rowspan="1" colspan="1">Jadad 5/5; 85% follow-up in these three arms</td>
              </tr>
            </tbody>
          </table>
        </alternatives>
        <table-wrap-foot>
          <fn id="nt101">
            <label>*</label>
            <p>BP not assessed in meta-analysis as both arms contained an anti-hypertensive;</p>
          </fn>
          <fn id="nt102">
            <label>**</label>
            <p>Following placebo 12 weeks of cross-over RCT;</p>
          </fn>
          <fn id="nt103">
            <label>#</label>
            <p>Double-blind 9-arm with varying medication components and number of components. Only three arms were used in this meta-analysis: the polycap, aspirin and simvastatin arms;</p>
          </fn>
          <fn id="nt104">
            <label/>
            <p>BP = blood pressure and measured in mmHg; SBP = systolic blood pressure; DBP = Diastolic blood pressure; Total chol. = total cholesterol in mmol/L; LDL = LDL cholesterol in mmol/L; AE = adverse events; TLC = therapeutic lifestyle changes; SD = standard deviation; CVD = cardiovascular disease.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <sec id="s3a">
        <title>Characteristics of Studies</title>
        <p>The intervention of all trials was a fixed dose combination that contained either one, two or three antihypertensives (including a calcium channel blocker <xref ref-type="bibr" rid="pone.0052145-Grimm1">[31]</xref>, <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref>, a thiazide and ACE inhibitor <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref>, <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref>, a thiazide, ACE inhibitor and beta-blocker <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref>, or a thiazide, angiotensin receptor blocker and a calcium channel blocker <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref>) plus one lipid lowering medication (including atorvastatin (20 mg) <xref ref-type="bibr" rid="pone.0052145-Grimm1">[31]</xref>, <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref>, <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref> or simvastatin (20 mg <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref>, <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref> or 40 mg <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref>)). Three ‘polypills’ also included aspirin (75 mg or 100 mg). <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref>, <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref>, <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref> The comparison was either a true placebo <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref>, <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref>, <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref> or one cardiovascular component (aspirin <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref>, simvastatin <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref> or amlodipine <xref ref-type="bibr" rid="pone.0052145-Grimm1">[31]</xref>). All trials were double-blind. Five were parallel designs and one was a cross-over design. <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref> One parallel trial included nine arms of varying numbers of fixed dose components but with no placebo arm. <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref> For this trial only the ‘polycap’ arm and the arms not containing an antihypertensive (‘aspirin arm’ and ‘statin arm’) for blood pressure comparisons and one arm not containing a lipid-lowering agent (‘aspirin arm’) for lipid comparisons were used. <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref> Five studies were of 6–12 weeks and one trial of 12 months duration. <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref> Two other randomised controlled trials of ‘polypills’ were identified but excluded. One study compared low-dose with high-dose polycap components but did not include a placebo arm or reduced number of components that allowed a placebo comparison of blood pressure or serum lipid concentrations. <xref ref-type="bibr" rid="pone.0052145-Yusuf3">[37]</xref> The other study was an open label trial comparing a ‘polypill’ with usual care. <xref ref-type="bibr" rid="pone.0052145-Soliman1">[38]</xref>.</p>
      </sec>
      <sec id="s3b">
        <title>Participant Characteristics</title>
        <p><xref ref-type="table" rid="pone-0052145-t001">Table 1</xref> summarises the study and participant characteristics. A total of 2,218 patients were included in the meta-analysis comparisons. This was made up of 1,116 in a ‘polypill’ group and 1,102 in a comparison group. No participants had previous cardiovascular disease but most had at least one cardiovascular risk factor. Despite this, there were some differences between study populations. Two trials excluded those with diabetes. <xref ref-type="bibr" rid="pone.0052145-Grimm1">[31]</xref>, <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref> Mean baseline systolic blood pressure varied from 125 mmHg <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref> to 147 mmHg <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref> in the intervention groups across trials and the proportion of women participants varied from 19% <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref> to 53%. <xref ref-type="bibr" rid="pone.0052145-Grimm1">[31]</xref> All trials except two <xref ref-type="bibr" rid="pone.0052145-The1">[35]</xref>, <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref> allowed concomitant blood-pressure lowering medication, although levels of use were low.</p>
      </sec>
      <sec id="s3c">
        <title>Effect on Blood Pressure</title>
        <p>Results from five trials, where control arms did not contain antihypertensive medication, were combined to assess effects of ‘polypills’ on blood pressure lowering (<xref ref-type="fig" rid="pone-0052145-g002">Figure 2</xref>). Compared with placebo, the ‘polypills’ reduced systolic blood pressure by −9.2 mmHg (95% confidence interval (CI): −13.4, −5.0) and diastolic blood pressure by −5.0 mmHg (95%CI: −7.4, −2.6). However, there was evidence of significant heterogeneity of trials (I<sup>2</sup> 87% and 83%, respectively). A sensitivity analysis including the four shorter trials of 6 to 12 weeks duration and excluding the longer trial of 12 months <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref>, found systolic blood pressure reduced by −10.8 mmHg (95%CI: −15.2, −6.3), and diastolic blood pressure by −6.0 mmHg (95%CI: −8.1, −4.0).</p>
        <fig id="pone-0052145-g002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052145.g002</object-id>
          <label>Figure 2</label>
          <caption>
            <title>Forest Plots of Polypills versus Control for Change in Systolic and Diastolic Blood Pressure.</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052145.g002" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3d">
        <title>Effect on Lipid Profiles</title>
        <p>Results from all trials, where the control did not contain lipid-lowering medication, were combined to assess effects on serum lipids (<xref ref-type="fig" rid="pone-0052145-g003">Figure 3</xref>). Compared with placebo, the ‘polypills’ reduced total cholesterol by −1.22 mmol/L (95%CI: −1.60, −0.84) and LDL-cholesterol by −1.02 mmol/L (95%CI: −1.37, −0.67). There was high statistical heterogeneity (I<sup>2</sup> = 96%). If the 12 month trial was excluded <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref>, total cholesterol reduced by −1.33 mmol/L (95%CI: −1.72, −0.95) and LDL-cholesterol by −1.13 mmol/L (95%CI: −1.47, −0.79).</p>
        <fig id="pone-0052145-g003" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052145.g003</object-id>
          <label>Figure 3</label>
          <caption>
            <title>Forest Plots of Polypills versus Control for Change in Total Cholesterol and LDL-cholesterol.</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052145.g003" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3e">
        <title>Discontinuation of Study Medication and Side Effects</title>
        <p>Those taking ‘polypills’ were more likely to discontinue medication compared with placebo or one component (20% vs 14%) (OR: 1.5 (95%CI: 1.2, 1.9); <xref ref-type="fig" rid="pone-0052145-g004">Figure 4</xref>). There was lower heterogeneity (I<sup>2</sup> = 21%) than for the estimates of effects on blood pressure or lipids. When only comparisons with placebo were included, <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref>, <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref>, <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref> the odds ratio was 1.7 (95%CI: 1.3, 2.3) (24% vs 16%). Amongst the four trials that reported overall side effects <xref ref-type="bibr" rid="pone.0052145-Grimm1">[31]</xref>, <xref ref-type="bibr" rid="pone.0052145-Neutel1">[32]</xref>, <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref>, <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref>, the difference between ‘polypills’ and comparison arms in the proportion experiencing side effects (36% vs 28%) was not statistically significant (OR: 1.3 (95%CI: 0.7, 2.5; I<sup>2</sup> = 73%) (<xref ref-type="fig" rid="pone-0052145-g004">Figure 4</xref>). The difference approached significance when only placebo-controlled trials were compared (45% vs 33%) (OR: 1.7 (95%CI: 0.97, 2.9)).</p>
        <fig id="pone-0052145-g004" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052145.g004</object-id>
          <label>Figure 4</label>
          <caption>
            <title>Forest Plots of Polypills versus Control for Change in Discontinuation of Study Medication and Side Effects.</title>
          </caption>
          <graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052145.g004" position="float" xlink:type="simple"/>
        </fig>
      </sec>
      <sec id="s3f">
        <title>Study Quality and Potential Bias</title>
        <p>Due to the high levels of heterogeneity, quality-effects models were also conducted and compared with the results from random-effects models, using MetaXL in Excel. <xref ref-type="bibr" rid="pone.0052145-Doi1">[27]</xref> Very similar effect estimates were obtained (<xref ref-type="supplementary-material" rid="pone.0052145.s002">Figure S2</xref>). Overall, included trials were of high quality (Jadad score 4/5 to 5/5), (<xref ref-type="table" rid="pone-0052145-t001">Table 1</xref>). However, there were differences in baseline systolic blood pressure between intervention and control groups in the trials of the Pill Collaborative Group and Malekzadeh et al. (4.0 and 5.5 mmHg, respectively). <xref ref-type="bibr" rid="pone.0052145-Pill1">[33]</xref>, <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref> The latter trial had imbalances in several baseline characteristics suggesting inadequacy of randomisation. <xref ref-type="bibr" rid="pone.0052145-Malekzadeh1">[34]</xref> It also had moderately high rates of attrition from both groups but more in the intervention group (31% vs 22%), representing another potential source of bias. Risk of bias in this trial was therefore “uncertain” according to Cochrane criteria (<xref ref-type="supplementary-material" rid="pone.0052145.s006">Table S3</xref>). <xref ref-type="bibr" rid="pone.0052145-Cochrane1">[24]</xref> There was no evidence of publication bias in any of the analyses (as evaluated by Begg’s and Egger’s tests and graphical representation using funnel plots (<xref ref-type="supplementary-material" rid="pone.0052145.s003">Figure S3</xref>)). The PRISMA checklist can be found for this meta-analysis in <xref ref-type="supplementary-material" rid="pone.0052145.s007">Table S4</xref>.</p>
      </sec>
    </sec>
    <sec id="s4">
      <title>Discussion</title>
      <sec id="s4a">
        <title>Summary of Findings</title>
        <p>Compared with placebo, the ‘polypills’ reduced systolic blood pressure by −9.2 mmHg, diastolic blood pressure by −5.0 mmHg, total cholesterol by −1.22 mmol/L and LDL-cholesterol by −1.02 mmol/L. Those taking a ‘polypill’ were more likely to discontinue study medication than those taking one component or placebo, although reported adverse effects were not significantly different.</p>
      </sec>
      <sec id="s4b">
        <title>Strengths and Limitations</title>
        <p>There was significant clinical and statistical heterogeneity amongst the trials. It may be argued that these studies should not have been combined in a meta-analysis because they contained interventions and controls with different components, and duration of follow-up varied from 6 weeks to 12 months. However, the meta-analysis assesses the use of cardiovascular ‘polypills’ in a variety of settings and populations, typical of real life, where at least one antihypertensive and one lipid-lowering medication have been combined in a fixed dose combination. Therefore, heterogeneity would be expected. Random-effects and quality-effects models found very similar effect sizes. <xref ref-type="bibr" rid="pone.0052145-Doi1">[27]</xref> There are also limitations with using summary level data rather than individual-level data in a meta-analysis.</p>
      </sec>
      <sec id="s4c">
        <title>Compared with the Literature and Implications for Future Practice</title>
        <p>This meta-analysis reviewed the current evidence for efficacy and tolerability of cardiovascular ‘polypills’. The ‘polypills’ reduced risk factors compared with placebo; although less than has been estimated previously. <xref ref-type="bibr" rid="pone.0052145-Wald1">[11]</xref> Wald et al estimated that a cardiovascular ‘polypill’ could reduce LDL cholesterol by 1.8 mmol/L and blood pressure by 20/11 mmHg. Actual reductions in risk factors depend on baseline risk factor levels and the number and doses of medications contained within the polypills. Wald’s estimated reduction in LDL cholesterol used a baseline of 4.8 mmol/L. <xref ref-type="bibr" rid="pone.0052145-Law2">[5]</xref> A 2003 meta-analysis of statin trials provides expected reductions in LDL based on statin and dose <xref ref-type="bibr" rid="pone.0052145-Law2">[5]</xref>, from which expected reductions in LDL can be estimated for each of the trials in this meta-analysis taking into account baseline LDL level (<xref ref-type="table" rid="pone-0052145-t002">Table 2</xref>). The ‘polypills’ in the trials included within this meta-analysis contained between one and three anti-hypertensives with doses of a quarter to twice the standard dose equivalent for each of these components (<xref ref-type="table" rid="pone-0052145-t002">Table 2</xref>). The observed reductions in systolic blood pressure and LDL-cholesterol for the ‘polypills’ were comparable to that expected for two of the trials (Neutel and Wald). Although the observed reduction in systolic blood pressure was comparable to that expected in the PILL collaborative trial, the observed reduction in LDL-cholesterol was only 64% of that expected. The observed reduction in LDL cholesterol in the Grimm trial was 89% of that expected. The observed reduction in systolic blood pressure and LDL-cholesterol were much less than expected in the Malekzadeh and TIPS trials. This discrepancy could be explained by the greater loss to follow up in these trials, which would dilute treatment effect when ‘intention to treat’ analyses are undertaken, a lower adherence rate than reported, concomitant treatment in the control groups or methodological issues. However, it may also be closer to the real change in risk factors likely if used in practice. The trial that found the greatest reductions in blood pressure and lipids was the trial that had few participants drop-out, good adherence, and no concomitant blood pressure and lipid-lowering medication. <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref> Almost all the participants had been taking the component medications prior to the trial, so presumably would be those most likely to tolerate and adhere to a combination ‘polypill’. <xref ref-type="bibr" rid="pone.0052145-Wald2">[36]</xref> For this type of patient, we can expect predicted results. The real test will be in comparing ‘polypills’ to current care.</p>
        <table-wrap id="pone-0052145-t002" position="float">
          <object-id pub-id-type="doi">10.1371/journal.pone.0052145.t002</object-id>
          <label>Table 2</label>
          <caption>
            <title>Actual vs Expected Reductions in Systolic Blood Pressure and LDL-cholesterol in Trials of ‘Polypills’.</title>
          </caption>
          <alternatives>
            <graphic id="pone-0052145-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0052145.t002" xlink:type="simple"/>
            <table>
              <colgroup span="1">
                <col align="left" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
                <col align="center" span="1"/>
              </colgroup>
              <thead>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Trial</td>
                  <td colspan="6" align="left" rowspan="1">Actual vs Expected Reductions in Systolic Blood Pressure (SBP)</td>
                  <td colspan="5" align="left" rowspan="1">Actual vs Expected Reductions in LDL-Cholesterol</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Antihypertensive</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Standard dose equivalent </italic>
                    <xref ref-type="bibr" rid="pone.0052145-Law3">[<italic>50</italic>]</xref>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Mean baseline SBP mm Hg</italic>
                    <xref ref-type="table-fn" rid="nt105">*</xref>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Expected reduction in</italic>
                    <italic>SBP mmHg</italic>
                    <xref ref-type="table-fn" rid="nt106">**</xref>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Observed mean difference in</italic>
                    <italic>SBP mmHg</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Observed/expected</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Statin</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Mean baseline LDL in mmol/l</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Expected reduction in</italic>
                    <italic>LDL mmol/l ?</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Observed control-adjusted reduction in LDL mmol/l</italic>
                  </td>
                  <td align="left" rowspan="1" colspan="1">
                    <italic>Observed/expected</italic>
                  </td>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Malekzadeh, 2010</td>
                  <td align="left" rowspan="1" colspan="1">Enalapril 2.5 mg</td>
                  <td align="left" rowspan="1" colspan="1">0.25</td>
                  <td align="left" rowspan="1" colspan="1">130</td>
                  <td align="left" rowspan="1" colspan="1">10.2 <xref ref-type="table-fn" rid="nt108">#</xref></td>
                  <td align="left" rowspan="1" colspan="1">2.4</td>
                  <td align="left" rowspan="1" colspan="1">24%</td>
                  <td align="left" rowspan="1" colspan="1">Atorvastatin 20 mg</td>
                  <td align="left" rowspan="1" colspan="1">2.99</td>
                  <td align="left" rowspan="1" colspan="1">1.29</td>
                  <td align="left" rowspan="1" colspan="1">0.45</td>
                  <td align="left" rowspan="1" colspan="1">35%</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Hydrochlorothiazide 12.5 mg</td>
                  <td align="left" rowspan="1" colspan="1">0.5</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Neutel, 2009</td>
                  <td align="left" rowspan="1" colspan="1">Amlodipine 5 mg</td>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1">150</td>
                  <td align="left" rowspan="1" colspan="1">8.7</td>
                  <td align="left" rowspan="1" colspan="1">8.3</td>
                  <td align="left" rowspan="1" colspan="1">95%</td>
                  <td align="left" rowspan="1" colspan="1">Atorvastatin 20 mg</td>
                  <td align="left" rowspan="1" colspan="1">3.46</td>
                  <td align="left" rowspan="1" colspan="1">1.49</td>
                  <td align="left" rowspan="1" colspan="1">1.55</td>
                  <td align="left" rowspan="1" colspan="1">104%</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">PILL collaboration, 2011</td>
                  <td align="left" rowspan="1" colspan="1">Lisinopril 10 mg</td>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1">130</td>
                  <td align="left" rowspan="1" colspan="1">10.2 <xref ref-type="table-fn" rid="nt109">##</xref></td>
                  <td align="left" rowspan="1" colspan="1">9.9</td>
                  <td align="left" rowspan="1" colspan="1">97%</td>
                  <td align="left" rowspan="1" colspan="1">Simvastatin 20 mg</td>
                  <td align="left" rowspan="1" colspan="1">3.65</td>
                  <td align="left" rowspan="1" colspan="1">1.17</td>
                  <td align="left" rowspan="1" colspan="1">0.75</td>
                  <td align="left" rowspan="1" colspan="1">64%</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Hydrochlorothiazide 12.5 mg</td>
                  <td align="left" rowspan="1" colspan="1">0.5</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Wald, 2012</td>
                  <td align="left" rowspan="1" colspan="1">Hydrochlorothiazide 12.5 mg</td>
                  <td align="left" rowspan="1" colspan="1">0.5</td>
                  <td align="left" rowspan="1" colspan="1">140</td>
                  <td align="left" rowspan="1" colspan="1">17.6</td>
                  <td align="left" rowspan="1" colspan="1">17.9</td>
                  <td align="left" rowspan="1" colspan="1">100%</td>
                  <td align="left" rowspan="1" colspan="1">Simvastatin 40 mg</td>
                  <td align="left" rowspan="1" colspan="1">3.70</td>
                  <td align="left" rowspan="1" colspan="1">1.37</td>
                  <td align="left" rowspan="1" colspan="1">1.4</td>
                  <td align="left" rowspan="1" colspan="1">102%</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Losartan 25 mg</td>
                  <td align="left" rowspan="1" colspan="1">0.5</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Amlodipine 2.5 mg</td>
                  <td align="left" rowspan="1" colspan="1">0.5</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">The Indian Polycap Study, 2009</td>
                  <td align="left" rowspan="1" colspan="1">Hydrochlorothiazide 12.5 mg</td>
                  <td align="left" rowspan="1" colspan="1">0.5</td>
                  <td align="left" rowspan="1" colspan="1">130</td>
                  <td align="left" rowspan="1" colspan="1">18.2<xref ref-type="table-fn" rid="nt110">β</xref></td>
                  <td align="left" rowspan="1" colspan="1">7.4</td>
                  <td align="left" rowspan="1" colspan="1">41%</td>
                  <td align="left" rowspan="1" colspan="1">Simvastatin 20 mg</td>
                  <td align="left" rowspan="1" colspan="1">3.00</td>
                  <td align="left" rowspan="1" colspan="1">0.96</td>
                  <td align="left" rowspan="1" colspan="1">0.72</td>
                  <td align="left" rowspan="1" colspan="1">75%</td>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Atenolol 50 mg</td>
                  <td align="left" rowspan="1" colspan="1">1</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1">Ramipril 5 mg</td>
                  <td align="left" rowspan="1" colspan="1">2</td>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                  <td align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td align="left" rowspan="1" colspan="1">Grimm, 2010</td>
                  <td align="left" rowspan="1" colspan="1">N/A</td>
                  <td align="left" rowspan="1" colspan="1">N/A</td>
                  <td align="left" rowspan="1" colspan="1">N/A</td>
                  <td align="left" rowspan="1" colspan="1">N/A</td>
                  <td align="left" rowspan="1" colspan="1">N/A</td>
                  <td align="left" rowspan="1" colspan="1">NA</td>
                  <td align="left" rowspan="1" colspan="1">Atorvastatin 20 mg</td>
                  <td align="left" rowspan="1" colspan="1">3.35</td>
                  <td align="left" rowspan="1" colspan="1">1.44</td>
                  <td align="left" rowspan="1" colspan="1">1.28</td>
                  <td align="left" rowspan="1" colspan="1">89%</td>
                </tr>
              </tbody>
            </table>
          </alternatives>
          <table-wrap-foot>
            <fn id="nt105">
              <label>*</label>
              <p>rounded to nearest 10 mm Hg;</p>
            </fn>
            <fn id="nt106">
              <label>**</label>
              <p>based on mean baseline SBP &amp; standard dose equivalence (from Law 2009) <xref ref-type="bibr" rid="pone.0052145-Law1">[4]</xref>;</p>
            </fn>
            <fn id="nt107">
              <label>∧</label>
              <p>mean baseline LDL × percentage reduction in LDL cholesterol for the statin at that dose (from Law 2003) <xref ref-type="bibr" rid="pone.0052145-Law2">[5]</xref></p>
            </fn>
            <fn id="nt108">
              <label>#</label>
              <p>estimate: two drugs at half dose therefore an overestimate of likely effect;</p>
            </fn>
            <fn id="nt109">
              <label>##</label>
              <p>estimate: two drugs at half dose therefore an underestimate of likely effect; 12.7 mmHg for two drugs at standard dose;</p>
            </fn>
            <fn id="nt110">
              <label>β</label>
              <p>estimate: three drugs at standard dose; 15.2 mmHg for three drugs at half standard dose.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>A short 12-week effectiveness trial comparing a ‘polypill’ with current care has been completed, but showed no difference between groups in systolic blood pressure or total cholesterol. <xref ref-type="bibr" rid="pone.0052145-Soliman1">[38]</xref> Several longer trials comparing a ‘polypill’ with current care are well underway or soon to be published. <xref ref-type="bibr" rid="pone.0052145-Liu1">[39]</xref>, <xref ref-type="bibr" rid="pone.0052145-Sanz1">[40]</xref>, <xref ref-type="bibr" rid="pone.0052145-Selak2">[41]</xref>, <xref ref-type="bibr" rid="pone.0052145-Zamorano1">[42]</xref>, <xref ref-type="bibr" rid="pone.0052145-Thom1">[43]</xref> The doses and number of components used will obviously influence both effectiveness and tolerability. A recent trial showed that doubling the doses of five ‘polypill’ components resulted in further significant reductions in systolic blood pressure (2.8 mmHg), diastolic blood pressure (1.7 mmHg), total cholesterol (0.19 mmol/L) and LDL-cholesterol (0.17 mmol/L). <xref ref-type="bibr" rid="pone.0052145-Yusuf3">[37]</xref>.</p>
        <p>Even if the effectiveness of the ‘polypill’ strategy is found only to be equivalent to current care, cost is likely to be reduced, making preventive therapies more affordable, particularly for low-income countries. <xref ref-type="bibr" rid="pone.0052145-Strong1">[22]</xref> A large part of the burden of chronic disease, particularly cardiovascular disease, is now borne by low-income countries. In 2005, it was estimated that 35 million people would die from non-communicable chronic diseases around the world. <xref ref-type="bibr" rid="pone.0052145-Strong1">[22]</xref> Cardiovascular disease was found to be the leading single cause of death and accounted for 20% of the total disability-adjusted years lost amongst people over 30 years of age globally. Furthermore, 80% of the burden of chronic disease occurs in people under the age of 70 years. <xref ref-type="bibr" rid="pone.0052145-Strong1">[22]</xref> Rates of preventive therapy are lower in low- and middle-income countries than in high-income countries. <xref ref-type="bibr" rid="pone.0052145-Lim1">[44]</xref> Patented medications have made many of the cardiovascular preventive medications prohibitively expensive for these countries, severely limiting access to medications, increasing levels of poverty <xref ref-type="bibr" rid="pone.0052145-Niens1">[45]</xref> and causing impoverishment in households struggling to afford medication. <xref ref-type="bibr" rid="pone.0052145-Banerjee1">[46]</xref> The use of affordable ‘polypills’ could help address this issue.</p>
        <p>A recent review of the cost-effectiveness of interventions for primary prevention of cardiovascular disease found that one of the ‘best value for money’ interventions was a combination of low cost blood pressure lowering medications and a statin, aimed at those at increased CVD risk. <xref ref-type="bibr" rid="pone.0052145-Cobiac1">[47]</xref> Modelled cost-effectiveness analyses of a ‘polypill’ have also been promising in middle and higher income countries. <xref ref-type="bibr" rid="pone.0052145-Liew1">[48]</xref>, <xref ref-type="bibr" rid="pone.0052145-vanGils1">[49]</xref> However, the actual clinical and economic potential of a polypill strategy will require the results of effectiveness trials that compare ‘polypills’ with current care and subsequent cost-utility analyses.</p>
      </sec>
    </sec>
    <sec id="s5">
      <title>Supporting Information</title>
      <supplementary-material id="pone.0052145.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0052145.s001" position="float" xlink:type="simple">
        <label>Figure S1</label>
        <caption>
          <p>
            <bold>‘Polypills’ meta-analysis flow diagram of a second literature search.</bold>
          </p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0052145.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0052145.s002" position="float" xlink:type="simple">
        <label>Figure S2</label>
        <caption>
          <p>
            <bold>Meta-analyses comparing ‘quality effects’ models with ‘random effects’ or Mantel Haenszel fixed effects models undertaken in Excel.</bold>
          </p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0052145.s003" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0052145.s003" position="float" xlink:type="simple">
        <label>Figure S3</label>
        <caption>
          <p>
            <bold>Funnel plots to assess for publication bias.</bold>
          </p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0052145.s004" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0052145.s004" position="float" xlink:type="simple">
        <label>Table S1</label>
        <caption>
          <p>
            <bold>Literature search terms and results, conducted by CRE.</bold>
          </p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0052145.s005" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0052145.s005" position="float" xlink:type="simple">
        <label>Table S2</label>
        <caption>
          <p>
            <bold>Literature search terms and results, conducted by AKG.</bold>
          </p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0052145.s006" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0052145.s006" position="float" xlink:type="simple">
        <label>Table S3</label>
        <caption>
          <p>
            <bold>Risk of bias of included studies, using the Cochrane collaboration criteria.</bold>
          </p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
      <supplementary-material id="pone.0052145.s007" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xlink:href="info:doi/10.1371/journal.pone.0052145.s007" position="float" xlink:type="simple">
        <label>Table S4</label>
        <caption>
          <p>
            <bold>PRISMA checklist.</bold>
          </p>
          <p>(DOCX)</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>We would like to thank the corresponding authors of the studies who contributed extra data and information for this meta-analysis.</p>
    </ack>
    <ref-list>
      <title>References</title>
      <ref id="pone.0052145-World1">
        <label>1</label>
        <mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2008) The global burden of disease: 2004 update. Geneva: World Health Organization: WHO website. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html" xlink:type="simple">http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html</ext-link> Accessed: August 2012.</mixed-citation>
      </ref>
      <ref id="pone.0052145-National1">
        <label>2</label>
        <mixed-citation publication-type="other" xlink:type="simple">National Institute for Health and Clinical Excellence (2011) Secondary prevention in primary and secondary care for patients following a myocardial infarction. UK: NHS website. Available: <ext-link ext-link-type="uri" xlink:href="http://publications.nice.org.uk/mi-secondary-prevention-cg48/introduction" xlink:type="simple">http://publications.nice.org.uk/mi-secondary-prevention-cg48/introduction</ext-link> Accessed: 8th June 2012.</mixed-citation>
      </ref>
      <ref id="pone.0052145-New1">
        <label>3</label>
        <mixed-citation publication-type="other" xlink:type="simple">New Zealand Guidelines Group (2012) New Zealand Primary Care Handbook 2012: Cardiovascular risk assessment and diabetes screening; Cardiovascular risk factor management; Management of type 2 diabetes. NZGG website. Available: <ext-link ext-link-type="uri" xlink:href="http://www.health.govt.nz/publication/new-zealand-primary-care-handbook-2012" xlink:type="simple">http://www.health.govt.nz/publication/new-zealand-primary-care-handbook-2012</ext-link> Accessed: November 2012.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Law1">
        <label>4</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Law</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Wald</surname><given-names>NJ</given-names></name> (<year>2009</year>) <article-title>Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies</article-title>. <source>BMJ</source> <volume>338</volume>: <fpage>b1665</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Law2">
        <label>5</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Law</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Wald</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Rudnicka</surname><given-names>AR</given-names></name> (<year>2003</year>) <article-title>Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis</article-title>. <source>BMJ</source> <volume>326</volume>: <fpage>1423</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Cholesterol1">
        <label>6</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Cholesterol Treatment Trialists’ (CTT) Collaborators</collab> (<year>2012</year>) <article-title>The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials</article-title>. <source>Lancet</source> <volume>6736</volume>: <fpage>60367</fpage>–<lpage>60365</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-AntithromboticTrialists1">
        <label>7</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Antithrombotic Trialists</surname><given-names>Collaboration</given-names></name> (<year>2002</year>) <article-title>Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients</article-title>. <source>BMJ</source> <volume>324</volume>: <fpage>71</fpage>–<lpage>86</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-US1">
        <label>8</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">U.S. Preventive Services Task Force</collab> (<year>2009</year>) <article-title>Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force Recommendation Statement</article-title>. <source>Ann Intern Med</source> <volume>150</volume>: <fpage>396</fpage>–<lpage>404</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Yusuf1">
        <label>9</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name> (<year>2002</year>) <article-title>Two decades of progress in preventing vascular disease</article-title>. <source>Lancet</source> <volume>360</volume>: <fpage>2</fpage>–<lpage>3</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Murray1">
        <label>10</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Murray</surname><given-names>CJL</given-names></name>, <name name-style="western"><surname>Lauer</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Hutubessy</surname><given-names>RCW</given-names></name>, <name name-style="western"><surname>Niessen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tomijima</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovscular-disease risk</article-title>. <source>Lancet</source> <volume>361</volume>: <fpage>717</fpage>–<lpage>725</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Wald1">
        <label>11</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wald</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Law</surname><given-names>M</given-names></name> (<year>2003</year>) <article-title>A strategy to reduce cardiovascular disease by more than 80%</article-title>. <source>BMJ</source> <volume>326</volume>: <fpage>1419</fpage>–<lpage>1424</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Elley1">
        <label>12</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Elley</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Kenealy</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bramley</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Selak</surname><given-names>V</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand</article-title>. <source>Diabetes Res Clin Pract</source> <volume>79</volume>: <fpage>468</fpage>–<lpage>473</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Yusuf2">
        <label>13</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Islam</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Rangarajan</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dagenais</surname><given-names>G</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey</article-title>. <source>Lancet</source> <volume>378</volume>: <fpage>1231</fpage>–<lpage>1243</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Selak1">
        <label>14</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Selak</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rafter</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Parag</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Tomlin</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hoorn</surname><given-names>SV</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Cardiovascular treatment gaps: Closing, but slowly</article-title>. <source>N Z Med J</source> <volume>122</volume>: <fpage>41</fpage>–<lpage>49</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-World2">
        <label>15</label>
        <mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2003) Adherence to Long-term Therapies: Evidence for action WHO website. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html" xlink:type="simple">http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html</ext-link> Accessed: August 2012.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Kulkarni1">
        <label>16</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kulkarni</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Lytle</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Heiss</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>ED</given-names></name> (<year>2006</year>) <article-title>Long-term adherence with cardiovascular drug regimens</article-title>. <source>Am Heart J</source> <volume>151</volume>: <fpage>185</fpage>–<lpage>191</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Chapman1">
        <label>17</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chapman</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Benner</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Petrilla</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Tierce</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Collins</surname><given-names>SR</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Predictors of adherence with antihypertensive and lipid-lowering therapy</article-title>. <source>Arch Intern Med</source> <volume>165</volume>: <fpage>1147</fpage>–<lpage>1152</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Gaziano1">
        <label>18</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gaziano</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Opie</surname><given-names>LH</given-names></name>, <name name-style="western"><surname>Weinstein</surname><given-names>MC</given-names></name> (<year>2006</year>) <article-title>Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis</article-title>. <source>Lancet</source> <volume>368</volume>: <fpage>679</fpage>–<lpage>686</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Lafeber1">
        <label>19</label>
        <mixed-citation publication-type="other" xlink:type="simple">Lafeber M, Spiering W, Singh K, Guggilla R, Patil V, <etal>et al</etal>.. (2011) The cardiovascular polypill in high-risk patients. Eur J Prev Cardiol <ext-link ext-link-type="uri" xlink:href="http://cpr.sagepub.com/content/early/2011/10/20/1741826711428066" xlink:type="simple">http://cpr.sagepub.com/content/early/2011/10/20/1741826711428066</ext-link>: 1–9; Accessed: August 2012.</mixed-citation>
      </ref>
      <ref id="pone.0052145-World3">
        <label>20</label>
        <mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2002) Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. World Health Organization - Wellcome Trust meeting report 1–3 August 2001, Geneva. WHO website. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/cardiovascular_diseases/media/en/615.pdf" xlink:type="simple">http://www.who.int/cardiovascular_diseases/media/en/615.pdf</ext-link> Accessed: November 2012.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Lonn1">
        <label>21</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lonn</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bosch</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Teo</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Pais</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Xavier</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions</article-title>. <source>Circulation</source> <volume>122</volume>: <fpage>2078</fpage>–<lpage>2088</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Strong1">
        <label>22</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Strong</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mathers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Leeder</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Beaglehole</surname><given-names>R</given-names></name> (<year>2005</year>) <article-title>Preventing chronic diseases: how many lives can we save?</article-title> <source>Lancet</source> <volume>366</volume>: <fpage>1578</fpage>–<lpage>1582</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Gupta1">
        <label>23</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gupta</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Arshad</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Poulter</surname><given-names>NR</given-names></name> (<year>2010</year>) <article-title>Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis</article-title>. <source>Hypertension</source> <volume>55</volume>: <fpage>399</fpage>–<lpage>407</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Cochrane1">
        <label>24</label>
        <mixed-citation publication-type="other" xlink:type="simple">Cochrane Collaboration (2011) Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. In: Higgins J, Green S, editors.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Jadad1">
        <label>25</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jadad</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Carroll</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jenkinson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>DJ</given-names></name>, <etal>et al</etal>. (<year>1996</year>) <article-title>Assessing the quality of reports of randomized clinical trials: is blinding necessary?</article-title> <source>Control Clin Trials</source> <volume>17</volume>: <fpage>1</fpage>–<lpage>12</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Furukawa1">
        <label>26</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Furukawa</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Barbui</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cipriani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brambilla</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>N</given-names></name> (<year>2006</year>) <article-title>Imputing missing standard deviations in meta-analyses can provide accurate results</article-title>. <source>J Clin Epidemiol</source> <volume>59</volume>: <fpage>7</fpage>–<lpage>10</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Doi1">
        <label>27</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Doi</surname><given-names>SAR</given-names></name>, <name name-style="western"><surname>Barendregt</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Mozurkewich</surname><given-names>EL</given-names></name> (<year>2011</year>) <article-title>Meta-analysis of heterogeneous clinical trials: an empirical example</article-title>. <source>Contemp Clin Trials</source> <volume>32</volume>: <fpage>288</fpage>–<lpage>298</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Begg1">
        <label>28</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Egger1">
        <label>29</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname><given-names>C</given-names></name> (<year>1997</year>) <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Sterne1">
        <label>30</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sterne</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Egger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>GD</given-names></name> (<year>2001</year>) <article-title>Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis</article-title>. <source>BMJ</source> <volume>323</volume>: <fpage>101</fpage>–<lpage>105</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Grimm1">
        <label>31</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Grimm</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yunis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sutradhar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kursun</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial</article-title>. <source>Vasc Health Risk Manag</source> <volume>6</volume>: <fpage>261</fpage>–<lpage>271</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Neutel1">
        <label>32</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Neutel</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Bestermann</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Dyess</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Graff</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kursun</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study</article-title>. <source>J Clin Hypertens</source> <volume>11</volume>: <fpage>22</fpage>–<lpage>30</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Pill1">
        <label>33</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">Pill Collaborative Group, Rodgers A, Patel A, Berwanger O, Bots M, et al</collab> (<year>2011</year>) <article-title>An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk</article-title>. <source>PLoS ONE</source> <volume>6</volume>: <fpage>e19857</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Malekzadeh1">
        <label>34</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Malekzadeh</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Marshall</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Pourshams</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gharravi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aslani</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy (‘polypill’) on cardiovascular risk factors</article-title>. <source>Int J Clin Pract</source> <volume>64</volume>: <fpage>1220</fpage>–<lpage>1227</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-The1">
        <label>35</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><collab xlink:type="simple">The Indian Polycap Study (TIPS)</collab> (<year>2009</year>) <article-title>Effects of a polypill (Polycap) on risk factors in middle-aged individuals wihtout cardiovascular disease (TIPS): a phase II, double-blind, randomised trial Lancet</article-title>. <volume>373</volume>: <fpage>1341</fpage>–<lpage>1351</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Wald2">
        <label>36</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wald</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Wald</surname><given-names>NJ</given-names></name> (<year>2012</year>) <article-title>Randomized polypill crossover trial in people aged 50 and over</article-title>. <source>PLoS ONE</source> <volume>7</volume>: <fpage>e41297</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Yusuf3">
        <label>37</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yusuf</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pais</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Sigamani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Xavier</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Afzal</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Comparison of Risk Factor Reduction and Tolerability of a Full-Dose Polypill (With Potassium) Versus Low-Dose Polypill (Polycap) in Individuals at High Risk of Cardiovascular Diseases: The Second Indian Polycap Study (TIPS-2) Investigators</article-title>. <source>Circ Cardiovasc Qual Outcomes</source> <volume>5</volume>: <fpage>463</fpage>–<lpage>471</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Soliman1">
        <label>38</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Soliman</surname><given-names>EZ</given-names></name>, <name name-style="western"><surname>Mendis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dissanayake</surname><given-names>WP</given-names></name>, <name name-style="western"><surname>Somasundaram</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Gunaratne</surname><given-names>PS</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization</article-title>. <source>Trials</source> <volume>12</volume>: <fpage>3</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Liu1">
        <label>39</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Patel</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Eades</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hayman</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: a randomised controlled trial of a polypill-based strategy amongst indigenous and non indigenous people at high cardiovascular risk</article-title>. <source>BMC Public Health</source> <volume>10</volume>: <fpage>458</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Sanz1">
        <label>40</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sanz</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Fuster</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Guzman</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Guglietta</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Arnaiz</surname><given-names>JA</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives</article-title>. <source>Am Heart J</source> <volume>162</volume>: <fpage>811</fpage>–<lpage>817.e811</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Selak2">
        <label>41</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Selak</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Elley</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Crengle</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Harwood</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Doughty</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Improving adherence using combination therapy (IMPACT): Design and protocol of a randomised controlled trial in primary care</article-title>. <source>Contemp Clin Trials</source> <volume>32</volume>: <fpage>909</fpage>–<lpage>915</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Zamorano1">
        <label>42</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zamorano</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Erdine</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lopez</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Al Khadra</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study</article-title>. <source>Postgrad Med</source> <volume>122</volume>: <fpage>7</fpage>–<lpage>15</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Thom1">
        <label>43</label>
        <mixed-citation publication-type="other" xlink:type="simple">Thom S, Field J, Poulter N, Patel A, Prabhakaran D, <etal>et al</etal>.. (2012) Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Preventive Cardiology.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Lim1">
        <label>44</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lim</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Gaziano</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Gakidou</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Reddy</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Farzadfar</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs</article-title>. <source>Lancet</source> <volume>370</volume>: <fpage>2054</fpage>–<lpage>2062</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Niens1">
        <label>45</label>
        <mixed-citation publication-type="other" xlink:type="simple">Niens LM, Cameron A, Van de Poel E, Ewen M, Brouwer WBF, <etal>et al</etal>.. (2010) Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med 7.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Banerjee1">
        <label>46</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hollis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pogge</surname><given-names>T</given-names></name> (<year>2010</year>) <article-title>The Health Impact Fund: incentives for improving access to medicines</article-title>. <source>Lancet</source> <volume>375</volume>: <fpage>166</fpage>–<lpage>169</lpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Cobiac1">
        <label>47</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cobiac</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Magnus</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lim</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Barendregt</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>R</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Which interventions offer best value for money in primary prevention of cardiovascular disease?</article-title> <source>PLoS ONE</source> <volume>7</volume>: <fpage>e41842</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Liew1">
        <label>48</label>
        <mixed-citation publication-type="other" xlink:type="simple">Liew D, Park H-J, Ko S-K (2009) Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clin Ther 31: 2189–2203; discussion 2150–2181.</mixed-citation>
      </ref>
      <ref id="pone.0052145-vanGils1">
        <label>49</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Gils</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>Over</surname><given-names>EAB</given-names></name>, <name name-style="western"><surname>Hamberg-van Reenen</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>de Wit</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>van den Berg</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population</article-title>. <source>BMJ Open</source> <volume>1</volume>: <fpage>e000363</fpage>.</mixed-citation>
      </ref>
      <ref id="pone.0052145-Law3">
        <label>50</label>
        <mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Law</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Wald</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Jordan</surname><given-names>RE</given-names></name> (<year>2003</year>) <article-title>Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials</article-title>. <source>BMJ</source> <volume>326</volume>: <fpage>1427</fpage>.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>